Replication-defective (E1+E3-deleted) human adenovirus muscle-specific transgene expression was demonstrated vectors are a promising means of therapeutic gene delivery in immunodeficient mice after local injection of AV into to skeletal muscle cells. Since the tropism of adenovirus muscles at an early age. In nonmuscle tissues (brain, liver, is nonselective, muscle-specific expression of systemically kidney, lung), the transgene expression was extremely low administered vectors can only be achieved by the use of even though in these tissues in situ polymerase chain reaca tissue-specific promoter/enhancer that is small enough tion showed as high an infectivity of the cells by the AV as to fit the insert capacity of the vector. We have generated in muscle. The relatively small size, the good efficiency and two replication-defective adenovirus recombinants (AV) in the muscle specificity of the MCK promoter would make it which the reporter gene (either firefly luciferase or E. coli ␤-ideal to drive the 6.3 kb (truncated) dystrophin cDNA in galactosidase) was driven by a truncated (1.35 kb) muscle first generation AV (with a limited (8 kb) insert capacity) creatine kinase (MCK) promoter/enhancer or by the fast designed for gene therapy of Duchenne muscular troponin I (TnI) promoter/enhancer. Highly efficient and dystrophy.
Introduction therapeutic protein-coding sequence driven by Gene therapy for genetic diseases consists of introducing promoter/enhancer elements that support adequate a normal gene into target cells to provide its normal proexpression levels in the target tissue. 1 tein product and correct the deleterious consequences of One area of focus in gene therapy research has been the genetic mutation (reviewed by Karpati and Acsadi). 1 dystrophin gene replacement for dystrophin deficiency In gene therapy regimens, tissue-specific expression of states. Replication-defective adenoviral vectors have been the transgene is highly desirable as it would minimize shown to be an effective means of introducing dystrophin possible toxicity and immunogenicity in nontarget cells.
cDNA into skeletal muscle fibers of dystrophin-deficient In principle, this can be achieved either by limiting vector mdx mice by direct injection or a systemic route of admindelivery to the cell type of interest, or by engineering istration. 1 Since adenovirus readily infects many cell tissue-specific gene regulatory elements into nonselective types, selective or preferential expression of dystrophin vectors to drive transgene expression.
in skeletal muscle (after the systemic route of A variety of vectors for the delivery of therapeutic administration) is not possible. Therefore, the use of genes into target cells have been considered. Particularly muscle-specific promoter/enhancer is the method of promising is the human adenovirus type 5 (reviewed by choice to assure muscle-specific expression of dystrophin Kozarsky and Wilson). 2 The adenoviral genome is well using adenoviral vectors. characterized, large portions of viral DNAs can be substiMany muscle-specific genes have been cloned and their tuted by other sequences, the recombinants are relatively regulatory sequences are being mapped and characstable, the recombinant virus can be grown to high titer terized. These include ␣-skeletal actin, [3] [4] [5] ␣-cardiac and no human malignancy is associated with this virus. 2 actin, 6-8 troponin I, 9 myosin light chain 2, 10 myosin heavy For gene therapy applications, a replication-deficient chain 11 and muscle creatine kinase (MCK). [15] [16] [17] Both muscle creatine kinase and troponin I have high expression levels in muscle and their promoter/enhancer Muscle-specific expression with adenoviral vector N Larochelle et al 466 dividing myoblasts, MCK is not expressed, but early after were sampled at 10 and 30 days after injection. Young mice were chosen to enhance transduction efficiency of myoblast fusion into myotubes, MCK mRNA expression is induced and continues to increase until MCK becomes muscle by AV, 29 and the use of immunodeficient animals (scid mice) minimized immune reaction that comprothe predominant creatine kinase isoform. [13] [14] Several ciselements have been identified that regulate expression of mises long-term transgene expression, as demonstrated previously. 30 As shown in Figure 2a , 10 days after direct MCK. The full length MCK promoter/enhancer (6.5 kb) consists of a muscle specific enhancer (E1) (−1050 to injection with AVMCKlux, skeletal muscle had the highest luciferase activity by far, approximately 10 4 -fold −1256 bp), the basal promoter in the 5′ untranslated region upstream of the first exon, and a second enhancer higher than was detected in liver. Only heart and lung (after systemic injection through the heart) had any sig-(E2) in the first intron [15] [16] [17] (Figure 1a ). Translation begins in exon 2, 3.2 kb downstream of the transcription nificant luciferase activity although the levels were more than 50-to 500-fold lower in comparison to skeletal initiation site. 16 While sequences between −4800 and −1800 bp do not significantly affect MCK gene muscle. AVMCKlux efficiently transduced different groups of muscles such as the gastrocnemius, quadriceps expression, 18 the E1 enhancer influences overall MCK expression and confers muscle specificity. 15 The 206 bp and tibialis anterior which all expressed high levels of luciferase activity 10 days after direct injection (Figure enhancer region has been delineated into several motifs which, when mutated, lead to diminished promoter 3). Luciferase activity persisted in the skeletal muscle of immunodeficient mice, with no loss of activity detected activity in skeletal and cardiac muscle. 19 Although the E2 enhancer is not essential for MCK gene activity, it does at the 30-day sampling time (Figure 2b) . Although there was a decrease in expression in lung and heart between increase expression levels of the basal promoter. 20 The other muscle-specific gene of interest is troponin 10 and 30 days, it is unclear whether, at these extremely low levels of expression, this represents a biologically sig-I. Three unlinked genes encode three distinct protein isoforms of troponin I: the fast and slow skeletal isoforms nificant phenomenon. Although AV has a broad range of infectivity, we veriand a cardiac muscle-specific isoform (TnIfast, TnIslow, TnIcardiac). [21] [22] [23] [24] The troponin I gene TnIfast is a fiberfied that lack of luciferase expression in tissues other than skeletal muscle, heart, diaphragm and lung was not simtype specific muscle gene encoding the fast fiber isoform of the contractile regulatory protein. 25, 26 During differenply due to lack of infection of these tissues by AV during these experiments. The presence of adenoviral nucleic tiation of transfected mouse myoblasts, the quail TnIfast gene undergoes a Ͼ100-fold transcriptional activation. 9 acid in the injected tissues was confirmed by an in situ PCR protocol in which DNA was amplified with primers This is mediated by a muscle-specific enhancer, internal regulatory element (IRE), a 148 bp DNA sequence located specific for the E4 region of AV and subsequently hybridized to E4 probe. As illustrated in Figure 4 , in the first intron of the gene which is sufficient to drive the transcriptional activation of a reporter gene during adenoviral sequences were detected solely in all of the injected tissues of scid mice (panels A, C and E) and not myoblast differentiation. 27 The IRE contains an E-box motif that is a functional binding site for the myoD family in control uninjected ones (panels B, D and F). Thus, all tissues are well infected but transgene expression is conof transcription factors. 28 Although the E-box is essential for IRE activity, two other elements are also required for fined to skeletal muscle. To date, mainly strong constitutive promoters such as enhancer activity. 28 In the present report we show that promoter/enhancer the viral ones have been used for gene transfer experiments into muscle with adenoviral vectors. To compare elements from MCK and TnI, incorporated into expression cassettes with reporter genes in adenoviral the efficiency of the MCK driven expression to that obtained with the RSV LTR, groups of young scid mice vectors, give rise to efficient and highly tissue-specific reporter gene expression in skeletal muscle.
were injected in skeletal muscles (gastrocnemius, quadriceps and tibialis anterior) on one side with AVMCK lux, and on the other side with AVRSVlux. Groups of animals
Results
were also injected in the liver, kidney, heart and brain with one or the other AV recombinant. In support of the The constructs which were used to generate the adenoviral recombinants AVMCKlux and AVTnIlacZ are results of Figure 2 , all the examined tissues, except for skeletal muscle, had extremely low luciferase activity depicted in Figure 1 . A 1.35 kb fragment containing the MCK E1 enhancer and promoter, but not the E2 enhancer after injection with AVMCKlux, with less than 5% of the expression detected with AVRSVlux (Table 1 ). In skeletal found in the first intron, was cloned into an expression vector to drive the firefly luciferase reporter gene (lux).
muscle, 40% of the luciferase levels obtained with AVRSVlux could be attained with AVMCKlux (Table 1) , After in vivo recombination in 293 cells with human AV type 5 carrying deletions of the E1 and E3 regions, high attesting to the effectiveness of MCK promoter/enhancer sequences incorporated into AVMCKlux. titer adenoviral recombinants were produced. AVTnIlacZ was generated in a similar manner using sequences spanAVTnIlacZ was characterized using the same experimental approach. After direct injection of AV recombining from −530 to +1640 of the quail TnI fast gene, encompassing 530 bp of 5′ flanking DNA and the nants into various tissues of scid mice, samples were analyzed by histochemical staining for ␤-galactosidase enhancer located in the first intron, to regulate the expression of E. coli ␤-galactosidase gene (lacZ) (Figure 1 ). activity ( Figure 5 ). Transgene expression was detected only in skeletal muscle and no other organs. QuantifiTo test the tissue specificity of the regulatory sequences which were present in the two AV recombinants, a series cation of ␤-galactosidase levels by a chemiluminescencebased assay confirmed the presence of high levels of proof in vivo experiments were carried out in young scid mice. AV recombinants were injected directly into skelduct in muscle compared to non-muscle tissue (6000 pg of ␤-galactosidase in injected gastrocnemius versus less etal muscle, heart, lung, brain, kidney and liver, which than 50 pg in injected brain, liver, heart and kidney).
nuclei which were positive for adenoviral E4 sequences were evident in all tissues examined, irrespective of the When AVTnIlacZ was administered systemically through injection into the left ventricle of the heart, no ␤-galactolack of ␤-galactosidase product (data not shown). These results with AdTnIlacZ, in addition to providing a second sidase-positive fibers were detected in the heart and diaphragm (data not shown). Efficient transduction by AV example of skeletal muscle-specific expression in adenovirus recombinants containing promoter/enhancer of all injected tissue was verified by in situ PCR analysis for the presence of adenoviral nucleic acids. Numerous elements from muscle genes, also directly illustrate that expression is in muscle fibers per se, and not in other tissue components.
Discussion
In adenovirus-mediated gene transfer, limiting gene expression to specific cell types can theoretically be achieved either by customizing the tropism of the virus, or by restricting expression of the transgene to the target tissue by a tissue-specific promoter. To date, no single cell surface molecule has been identified which is absolutely specific to skeletal muscle, hindering the development of adenoviral vectors in which capsid proteins have been modified for attachment to, and infection of, only skeletal muscle. On the other hand, the regulatory sequences which govern expression of many different muscle-specific genes have been mapped, allowing control of gene expression through the use of these specific cis-acting elements. However, in the first generation adenoviral vectors, there are limitations on the size of promoter/cDNA expression cassette that can be inserted and packaged. This is even more important for correction of dystrophin deficiency since the smallest cDNA fragment which can be used functionally to replace the fulllength dystrophin, the Becker 'mini-gene', is 6.3 kb in length. Hence, there is a need for identifying the minimal sequences required for efficient and muscle-specific expression to be included in adenoviral vectors. In the newest version of the adenovirus vector, the insert capacity was increased to 28 kb by deleting the entire AV genome. 31 While in such a vector the full-length MCK promoter/enhancer was shown to drive dystrophin cDNA in vitro, a systematic study of tissue specificity of cific expression of the reporter genes used. Even when directly injected at high titers into other organs in whose cell nuclei adenoviral nucleic acids were easily detectable, expression of the reporter genes was several magnitudes lower as determined with sensitive assays (and can be considered negative for all practical purposes). In previous reports on the use of tissue-specific promoters in adenoviral vectors, [32] [33] [34] [35] [36] only a partial specificity was observed in many cases when different cell types and tissues were examined. 32, 35 It has been postulated that adenoviral sequences, especially the E1A enhancer which is present at position 194-380 of the E1A/E1B deleted adenoviral vector, might interfere with the tissue-specific regulatory elements. 35, 37 In the adenoviral recombinants used here, the E1A enhancer which is situated at the 3′ end of the transcriptional unit does not compromise the effect of the muscle-specific elements.
With both MCK and TnI regulatory sequences, high levels of reporter gene expression were achieved and maintained for at least 30 days in immunodeficient hosts. Luciferase levels produced by AVMCKlux compared fav- highly significant considering that the LTR of RSV is most active in skeletal muscle. 29 Taken together, the data indicate that engineering the adenoviral vector to be muscle-specific did not diminish efficiency of expression.
Figure 4 Analysis of adenoviral nucleic acids by in situ PCR in scid muscle (A, B), liver (C, D) and brain (E, F) which had been directly injected with AVMCKlux (A, C, E) or saline (B, D, F). Nuclei positive for AV sequences were detected only in tissues which had been injected with AVMCKlux. Magnification: A, × 350; B-F: × 650.
ary myocardiocytes 38 and/or alveolar macrophages 15 in phosphorylase deficiency in which the enzyme is expressed in fast fibers, the use of an expression cassette in AVTnI would be advantageous in delivering the gene product. When the pattern of expression observed in Figure 2 Several groups have used the 206 bp region of the E1 is compared with that reported with transgenic mice enhancer of MCK in conjunction with heterologous procontaining different copies of integrated MCK moters to obtain muscle-specific expression of transpromoter/reporter constructs, it is evident that AVMCK genes. 40, 41 Although these experiments have been sucis regulated in various tissues in a manner similar to that cessful in vitro, regulation in vivo is clearly different since of constructs containing the longer fragment of MCK recent analysis in transgenic mice has shown that the upstream sequences (−3300MCK CAT). 15 One exception 1 kb region between the basal promoter and the enhancer seems to be in cardiac muscle where expression levels is required, producing a 100-fold increase in expression with AVMCKlux were low, indicating that additional levels of reporter genes. 42 Thus, it is unlikely that the regulatory sequences may need to be included (or MCK regulatory sequences included in AVMCKlux excluded) eventually to correct the defect in DMD cardiac can be further trimmed. However, both the MCK muscle. In experiments in which animals were injected promoter/enhancer and the TnI promoter/enhancer by the intracardiac route, expression was detected in diaused in this study are small enough to drive the Beckerphragm and lung in addition to heart. In the type mini-dystrophin gene in the newly developed −3300MCKCAT transgenic mice, lung and brain have the adenoviral vectors with larger (10 kb) insert capacity that highest reporter gene levels after skeletal and cardiac have a realistic promise for gene therapy of DMD. 43, 44 muscle. 15 This is consistent with the presence of pulmon- 
Figure 5 Histochemical analysis of ␤-galactosidase activity in the gastrocnemius (A) and quadriceps muscles (B) as well as liver (C) and brain (D) of scid mice which had been directly injected with AVTnIlacZ as described in the Materials and methods. Tissues in C and

day-old scid mice injected directly into left cardiac
Materials and methods ventricle as described.
46
To compare the efficacy of the MCK promoter/ Construction of recombinant adenoviruses enhancer with RSV (Rous sarcoma virus) promoter, tib-A muscle creatine kinase enhancer/promoter driving the ialis anterior, quadriceps and gastrocnemius of 3-4-dayexpression of the luciferase gene was cloned as an old scid mice were injected with 10 l of each viral susexpression cassette into a plasmid containing sequences pension, at the same titer; the right sides of five mice from human adenovirus type 5. The MCK fragment conwere injected with AVMCKlux and left sides with tains the region from −1354 to +1 bp from the transcripAVRSVlux. In addition, the liver, kidney and brain of six tion initiation site. The fragment was amplified by PCR, scid mice were also directly injected with 10 l of using the full length MCK enhancer/promoter unit (6.5
AVRSVlux suspension, while the left cardiac ventricle of kb) as a template (a gift of JS Chamberlain, University of three scid mice was injected with 25 l of AVRSVlux susMichigan Medical School), 45 and BglII and HindIII sites pension. All mice were killed after 10 days. were added for cloning purposes.
For the experiments with AVTnIlacZ virus, 7-day-old The quail genomic sequences troponin I (−530 to +1604) scid mice (four animals) were directly injected in tibialis linked to the lacZ gene was cloned into a plasmid conanterior, liver and brain with 5, 20 and 20 l of AV sustaining sequences from human adenovirus type 5.
pension, respectively (7 × 10 11 particles per milliliter). The homologous recombination of the replicationThey were killed 30 days after injection. defective human adenovirus type 5 with the cassetted reporter genes, the large-scale production, purification and titration of the recombinant AV have been described
Analysis of the reporter gene expression For luciferase quantification, the dissected organs were in detail previously. 29 homogenized and centrifuged as described 29 and a mixture of the supernatant and commercial luciferin was Animals and injection techniques Experiments were performed on groups of scid mice tested for luciferase activity in a luminometer (Bio Orbit, Turku, Finland). The luciferase activity was converted to (Jackson Laboratories, Bar Harbour, ME, USA). The study was conducted in accordance with the guidelines of the pg of luciferase per mg of tissue as described.
29
For ␤-galactosidase quantification, dissected tissues Canadian Council of Animal Care. Scid mice (4-7-dayold) were anesthetized by intraperitoneal injection with and organs were lysed with 200 l of lysis buffer (100 mm potassium phosphate pH 7.8, 0.2% Triton X-100 and 0.3-0.4 ml of avertin (2.5% tribromoethyl alcohol and 2.5% amyl alcohol) in normal saline. Quadriceps, tibialis fresh 1 mm dithiothreitol) by homogenizing extracts with a plastic pestle in a microfuge tube, then spun down in anterior and gastrocnemius muscles (four animals) were injected percutaneously with 5 l of AVMCKlux suspena microcentrifuge. The ␤-galactosidase activity was analyzed using the chemiluminescent reporter assay for the sion (7 × 10 11 particles per milliliter). In addition, liver, kidney, brain and heart (three animals each) were detection of ␤-galactosidase (Tropix, Bedford, MA, USA) and read with BioOrbit luminometer (LKB-Fisher, Turku, directly injected with 20, 20, 20 and 30 l of AVMCKlux suspension, respectively. All mice were killed at 10 and Finland). A 20 l portion of the 200 l supernatant was added to 200 l of reaction buffer and incubated for 30 30 days after injection. The level of luciferase activity for the lung was determined after systemic injection of 4-7-min at room temperature. For each individual sample, the ␤-galactosidase activity (given in mV which equals at 42°C overnight as previously described. 47 Hybridization products were detected immunologically using an the integrated light emission for 10 s) was calculated for the entire tissue and converted to pg of pure ␤-galactoalkaline-phosphatase-conjugated anti-digoxigenin antibody according to the manufacturer's recommendations. sidase protein using a standard curve of ␤-galactosidase (Boehringer Mannheim, Laval, Quebec, Canada). The
Immunoreactivity was revealed by incubation with nitrobluetetrazolium and 5-bromo-4-chloro-3-indolyl phosdata were then statistically analyzed by analysis of variance (ANOVA) tests.
phate; positive reactions were easily detectable by blue staining of nuclei. Slides were counterstained with 1% For ␤-galactosidase histochemistry, 10-m serial sections were prepared, fixed in 1.5% glutaraldehyde eosin. Controls for the in situ PCR included muscle sections and stained for ␤-galactosidase activity as described. 29 The tissue sections were lightly counterstained with of mice which had not been injected with AV and the omission of Taq DNA polymerase or primers. Controls hematoxylin and eosin.
for in situ hybridization and detection included hybridization of samples without prior in situ PCR and hybridizIn situ PCR hybridization In situ PCR and hybridization were carried out to detect ation of in situ PCR samples with omission of probes. adenoviral DNA in nuclei of muscle fibers of mice which had been injected with AV. In situ PCR was performed Acknowledgements as previously described with the following modifications. 47, 48 We thank Dr Jeffrey Chamberlain for providing the plasIn brief, muscles of mice were cut into 6-m thick secmid containing the MCK promoter. This work was suptions, placed on glass slides (Perkin Elmer, Foster City, ported by the Muscular Dystrophy Association USA, the CA, USA) and dehydrated. PCR System 1000 using 500 ng/ml of the labelled probe
